Research programme: anticancer therapeutics - TheramexAlternative Names: TX D
Latest Information Update: 21 Aug 2007
At a glance
- Originator Theramex SAM
- Mechanism of Action Estrogen receptor antagonists; Sulfatase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 08 Sep 2004 Preclinical trials in Breast cancer in Monaco (unspecified route)